title: Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications.
abstract: We investigated thrombin activatable fibrinolysis inhibitor (TAFI) and its influence on fibrinolysis by measuring pro-TAFI activity and total TAFI antigen in 38 patients with type I diabetes mellitus (18 with and 20 without microvascular complications), as well as in 20 healthy controls. The pro-TAFI levels in the two groups of patients did not differ from those in the control group. Total TAFI antigen [i.e. pro-TAFI, TAFI and inactive carboxypeptidase U (TAFIi)] tended to decrease in both the patient groups (59.7 +/- 7.2 and 73.4 +/- 8.9% with and without microvascular complications, respectively) compared with controls (91.9 +/- 12.2%) (P = 0.12). We also assessed the overall hemostatic potential (OHP) in plasma, the clot lysis time and the overall fibrinolytic potential. The OHP was significantly higher in patients with complications compared with controls (8.9 +/- 0.9 versus 6.7 +/- 0.4; P < 0.05) and also higher in the diabetics without complications (7.8 +/- 0.6), although the latter difference did not reach statistical significance. Levels of clot lysis time and overall fibrinolytic potential were similar in the two groups of patients and the controls. The increased OHP in plasma from diabetic patients with microvascular complications indicates an imbalance of the hemostatic system towards a prothrombotic state. No signs of impaired fibrinolysis were observed in patients with diabetes. Using the OHP method for estimation of overall hemostasis, it seems that TAFI does not influence either fibrinolysis or the increased thrombotic potential observed in patients with type I diabetes mellitus.
authors.affiliation: Department of Surgical Sciences, Karolinska Institutet, Karolinska Institutet, Stockholm, Sweden. Jovan. Antovic@kirurgi.ki.se
authors.forename: Jovan P
authors.initials: JP
authors.lastname: Antovic
authors.forename: Marianne
authors.initials: M
authors.lastname: Yngen
authors.forename: Claes-Göran G
authors.initials: CG
authors.lastname: Ostenson
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Antovic
authors.forename: Håkan N
authors.initials: HN
authors.lastname: Wallen
authors.forename: Gun
authors.initials: G
authors.lastname: Jorneskög
authors.forename: Margareta
authors.initials: M
authors.lastname: Blombäck
mesh_terms: D000328:Adult; D025901:Carboxypeptidase B2 / Q000097:blood* / Q000502:physiology; D016022:Case-Control Studies; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000150:complications; D005260:Female; D005337:Fibrin / Q000378:metabolism; D005342:Fibrinolysis; D006487:Hemostasis; D006801:Humans; D008297:Male; D008833:Microcirculation / Q000503:physiopathology; D008875:Middle Aged; D019851:Thrombophilia
chemical_list: D005337:Fibrin; D025901:Carboxypeptidase B2